Tags

Type your tag names separated by a space and hit enter

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2002 Oct 15; 166(8):1084-91.AJ

Abstract

This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). A total of 691 patients with COPD received the combination of F and S (FSC), S (50 mcg), F (500 mcg), or placebo twice daily via the Diskus device for 24 weeks. A significantly greater increase in predose FEV(1) at the endpoint was observed after FSC (156 ml) compared with S (107 ml, p = 0.012) and placebo (-4 ml, p < 0.0001). A significantly greater increase in 2-hour postdose FEV(1) at the endpoint was observed after treatment with FSC (261 ml) compared with F (138 ml, p < 0.001) and placebo (28 ml, p < 0.001). There were greater improvements in the Transition Dyspnea Index with FSC (2.1) compared with F (1.3, p = 0.033), S (0.9, p < 0.001), and placebo (0.4, p < 0.0001). The incidence of adverse effects (except for an increase in oral candidiasis with FSC and F) was similar among the treatment groups. We conclude that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo.

Authors+Show Affiliations

Dartmouth Hitchcock Medical Center, Section of Pulmonary and Critical Care Medicine, 1 Medical Center Drive, Lebanon, NH 03756-0001, USA. donald.a.mahler@hitchcock.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

12379552

Citation

Mahler, Donald A., et al. "Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered Via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease." American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 8, 2002, pp. 1084-91.
Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084-91.
Mahler, D. A., Wire, P., Horstman, D., Chang, C. N., Yates, J., Fischer, T., & Shah, T. (2002). Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 166(8), 1084-91.
Mahler DA, et al. Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered Via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2002 Oct 15;166(8):1084-91. PubMed PMID: 12379552.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. AU - Mahler,Donald A, AU - Wire,Patrick, AU - Horstman,Donald, AU - Chang,Chai-Ni, AU - Yates,Julie, AU - Fischer,Tracy, AU - Shah,Tushar, PY - 2002/10/16/pubmed PY - 2003/5/13/medline PY - 2002/10/16/entrez SP - 1084 EP - 91 JF - American journal of respiratory and critical care medicine JO - Am J Respir Crit Care Med VL - 166 IS - 8 N2 - This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). A total of 691 patients with COPD received the combination of F and S (FSC), S (50 mcg), F (500 mcg), or placebo twice daily via the Diskus device for 24 weeks. A significantly greater increase in predose FEV(1) at the endpoint was observed after FSC (156 ml) compared with S (107 ml, p = 0.012) and placebo (-4 ml, p < 0.0001). A significantly greater increase in 2-hour postdose FEV(1) at the endpoint was observed after treatment with FSC (261 ml) compared with F (138 ml, p < 0.001) and placebo (28 ml, p < 0.001). There were greater improvements in the Transition Dyspnea Index with FSC (2.1) compared with F (1.3, p = 0.033), S (0.9, p < 0.001), and placebo (0.4, p < 0.0001). The incidence of adverse effects (except for an increase in oral candidiasis with FSC and F) was similar among the treatment groups. We conclude that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/12379552/Effectiveness_of_fluticasone_propionate_and_salmeterol_combination_delivered_via_the_Diskus_device_in_the_treatment_of_chronic_obstructive_pulmonary_disease_ L2 - https://www.atsjournals.org/doi/10.1164/rccm.2112055?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -